Divi's Laboratories Limited

Stocks

DIVISLAB

INE361B01024

Delayed NSE India S.E. Other stock markets 11:59:25 09/06/2026 am IST			5-day change	1st Jan Change
6,728.50 ^INR	+3.18%		+2.95%	+5.21%

26/05	Divi's Laboratories Limited announces Annual dividend, payable on September 09, 2026	CI
25/05	Choice Equity Upgrades Divi's Laboratories to Add from Reduce; Price Target is INR7,375	MT

Transcript : Divi's Laboratories Limited, Q3 2022 Earnings Call, Feb 11, 2022

Published on 02/11/2022 at 02:00 pm IST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Ladies and gentlemen, good day, and welcome to the earnings conference call of Divi's Laboratories Limited for the Q3 of financial year 2022. [Operator

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Divi's Laboratories Limited

26/05	Divi's Laboratories Limited announces Annual dividend, payable on September 09, 2026	CI
25/05	Choice Equity Upgrades Divi's Laboratories to Add from Reduce; Price Target is INR7,375	MT
25/05	Jefferies Adjusts Divi's Laboratories' Price Target to INR7,950 from INR8,100, Keeps at Buy	MT
25/05	Divi's Laboratories Clocks Gains in Fiscal Q4 Consolidated Profit	MT
24/05	Divi's Laboratories Limited, Q4 2026 Earnings Call, May 23, 2026
23/05	Divi's Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
01/04	Avendus Spark Upgrades Divi's Laboratories to Reduce from Sell, Price Target is INR5,840	MT
12/02	Jefferies Adjusts Divi's Laboratories' Price Target to INR8,100 From INR8,000, Keeps at Buy	MT
11/02	Divi's Laboratories Limited, Q3 2026 Earnings Call, Feb 11, 2026
11/02	Divi's Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
11/02	Indian contract drug maker Divi's misses profit view on high material costs, one-off labour charge	RE
11/02	Divi's Laboratories Q3 consol net profit 5.83 billion rupees	RE
14/11	Divi's Labs Unit-I inspection by US FDA concluded	RE
10/11	Jefferies Adjusts Divi's Laboratories' Price Target to INR7,850 From INR7,150, Keeps at Buy	MT
07/11	Divi's Laboratories Limited, Q2 2026 Earnings Call, Nov 07, 2025